We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 185

Celgene v. Canada
  • Gowling WLG
  • Canada
  • June 24 2009

Celgene is the current owner of several patents relating to thalidomide


Merck triumphs as new and inventive dosing regimen held patentable
  • Gowling WLG
  • United Kingdom
  • May 29 2008

Actavis sued to revoke Merck's patent with a second medical use claim (in the so-called 'Swiss form') for the use of finasteride in the preparation for a drug to treat androgenic alopecia with a lower dosage than disclosed in the prior art


Sanofi-Aventis v. Laboratoire Riva; interlocutory motion on 55.2 proceeding; December 14, 2007 - Ramipril
  • Gowling WLG
  • Canada
  • January 17 2008

After cross-examinations had taken place, and approximately one week before the application record of Sanofi-Aventis was due, Riva brought a motion for leave to file further evidence


Federal court affirms standing for innovative drug manufacturer
  • Gowling WLG
  • Canada
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the


PMPRB issues discussion paper on options to address the Federal Court decision in LEO Pharma
  • Gowling WLG
  • Canada
  • February 6 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper outlining a series of options to address the implications of the Federal Court of Canada decision in the LEO Pharma case


Recent cases
  • Gowling WLG
  • Canada
  • August 1 2008

The Court of Appeal overturned the motions judge's decision striking the notice of appearance


Data protection: defining innovative drug in Canada
  • Gowling WLG
  • Canada
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994


Implemention of “Bolar” in the EU
  • Gowling WLG
  • European Union, United Kingdom
  • October 31 2007

In Europe, Directive 200427EC (amending Directive 200183EC) introduced into European Union legislation for the first time an exemption from patent infringement for conducting certain developmental work pre-patent expiry (the EU ‘Bolar’ exemption


Apotex defeats French hypertension drug patent
  • Gowling WLG
  • United Kingdom
  • October 31 2007

The High Court found that a patent for a drug used to treat hypertension was infringed by Apotex’s generic equivalent


Les Laboratoires Servier v Apotex; interlocutory motion to quash subpoena; March 7, 2008; perindopril
  • Gowling WLG
  • Canada
  • April 21 2008

Motions were brought to quash seven subpoenas that required five lawyers, a patent agent and an administrative assistant to attend at trial to testify and produce certain documents